FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Aug. 23, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain purchasers of shares of Avinger Inc (NASDAQ:AVGR) over alleged violations of Federal Securities Laws by Avinger Inc in connection with Avinger’s initial public offering (“IPO”).
Investors, who purchased shares of Avinger Inc (NASDAQ:AVGR), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff claims that the IPO Registration Statement and Prospectus materially and falsely failed to disclose that Avinger lacked adequate personnel to increase sales of its lumivascular-platform products and to commercialize Pantheris, that Avinger experienced problems with the robustness of its lumivascular-platform devices (including Pantheris), that physicians and hospitals were requiring more extensive training concerning Avinger’s products as compared to competing products, that Avinger would not be able to rapidly ramp up sales of its lumivascular platform, and that as a result, Avinger experienced lower than expected sales and revenues.
Those who purchased Avinger Inc (NASDAQ:AVGR) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
